Family psychoeducation for major depressive disorder – study protocol for a randomized controlled trial

Abstract

BackgroundMajor depressive disorder has been shown to affect many domains of family life including family functioning. Conversely, the influence of the family on the course of the depression, including the risk of relapse, is one reason for targeting the family in interventions. The few studies conducted within this area indicate that family psychoeducation as a supplement to traditional treatment can effectively reduce the risk of relapse in patients with major depression as well as being beneficial for the relatives involved. However, the evidence is currently limited. This study will investigate the effect of family psychoeducation compared to social support on the course of the illness in patients with major depressive disorder.Method/designThe study is designed as a dual center, two-armed, observer-blinded, randomized controlled trial. Relatives are randomized to participate in one of two conditions: either four sessions of manualized family psychoeducation or four sessions in a social support group led by a health care professional. Patients will not participate in the groups and will continue their treatment as usual. A total of 100 patients, each accompanied by one relative, will be recruited primarily from two outpatient clinics in the Capital Region of Denmark.The primary outcome is the occurrence of depressive relapse at 9-month follow-up defined as a score ≥7 on the Hamilton six-item subscale. Secondary outcomes will include time to relapse.DiscussionIt is hoped that the results from this study will help to clarify the mechanisms behind any beneficial changes due to family psychoeducation and provide information on the long-term effect of this intervention for both patient and relatives. If the results are positive, the family psychoeducation program may be suitable for implementation within a clinical setting.Trial registrationClinicalTrials.gov Identifier: NCT02348827, registered 5 January 2015.

Effectiveness of therapeutic milieu intervention on inpatients with depressive disorder: A feasibility study from North India

“…It strengthened the patient's sense of self, behavioural control, and social interaction skills. In this study, there was a significant improvement in depression, self‐esteem, and socio‐occupational functioning among the TMI group 36,40–44 …”

Imagery rehearsal therapy and/or mianserin in treatment of refugees diagnosed with PTSD: Results from a randomized controlled trial

“…The following self‐administered rating scales were used: frequency and severity of nightmares were measured with the Disturbing Dreams and Nightmare Severity Index (DDNSI) (Krakow, 2006 ); severity of PTSD symptoms was measured with The Harvard Trauma Questionnaire (HTQ) (Hollifield et al., 2002 ); severity of anxiety (10 questions) and depression (15 questions) was measured with the Hopkins Symptom Check List (HSCL‐25) (Mollica et al., 1987 ); quality of life was measured with WHO‐5 (Timmerby et al., 2016 ); and functional impairment was measured with the Sheehan Disability Scale (SDS) (Sheehan & Sheehan, 2008 ).…”

Treatment of sleep disturbances in trauma-affected refugees: Study protocol for a randomised controlled trial

“…This is a short version of the Symptom Checklist-90 (SCL-90) [ 45 ] The World Health Organisation-Five Well-being Index (WHO-5) is a self-administered questionnaire evaluating quality of life, consisting of five questions. The questionnaire has been used to assess quality of life in a number of psychiatric diagnostic groups [ 53 , 54 ]. In addition, the scale has been used to assess overall treatment effects in the field of psychiatry [ 49 ] The Sheehan Disability Scale (SDS) is a self-administered rating scale measuring functional impairment with regard to family, work and social network using three visual analogue scales from 0 to 10.…”

“…The World Health Organisation-Five Well-being Index (WHO-5) is a self-administered questionnaire evaluating quality of life, consisting of five questions. The questionnaire has been used to assess quality of life in a number of psychiatric diagnostic groups [ 53 , 54 ]. In addition, the scale has been used to assess overall treatment effects in the field of psychiatry [ 49 ]…”